United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ubidecarenone - oral solution - 5mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ubidecarenone - oral drops - 5mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ubidecarenone - oral solution - 6mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ubidecarenone - oral suspension - 5mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ubidecarenone - oral solution - 10mg/1ml

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg/ml and 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies ). - dementia with lewy bodies (see warnings, neurological adverse reactions in

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - haloperidol decanoate, quantity: 70.52 mg/ml (equivalent: haloperidol, qty 50 mg/ml) - injection, solution - excipient ingredients: benzyl alcohol; sesame oil - haldol decanoate is indicated for the maintenance therapy of psychoses in adults; particularly for patients requiring prolonged parenteral neuroleptic therapy

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - nandrolone decanoate (unii: h45187t098) (nandrolone - unii:6pg9vr430d) - injection - nandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. surgically induced anephric patients have been reported to be less responsive. - male patients with carcinoma of the breast or with known or suspected carcinoma of the prostate. male patients with carcinoma of the breast or with known or suspected carcinoma of the prostate. - carcinoma of the breast in females with hypercalcemia: androgenic anabolic steroids may stimulate osteolytic resorption of bones. carcinoma of the breast in females with hypercalcemia: androgenic anabolic steroids may stimulate osteolytic resorption of bones. - pregnancy, because of masculinization of the fetus. pregnancy, because of masculinization of the fetus. - nephrosis or the nephrotic phase of nephritis. nephrosis or the nephrotic phase of nephritis. nandrolone decanoate injection is classified as a schedule iii controlled substance under the anabolic steroids control act of

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ubidecarenone - oral solution - 20mg/1ml

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - ubidecarenone - orange tablet, diameter 7.4 mm, thickness 4.5 mm